Glossary

Deutsch: Höhenkrankheit / Español: Mal de altura / Português: Mal de altitude / Français: Mal aigu des montagnes / Italiano: Mal di montagna

Altitude sickness, also referred to as acute mountain sickness (AMS), is a pathological condition that occurs when individuals ascend to high elevations too rapidly, resulting in insufficient acclimatization to reduced oxygen levels. This syndrome is particularly relevant in travel and tourism, where visitors to mountainous regions or high-altitude destinations may experience symptoms ranging from mild discomfort to life-threatening complications.

General Description

Altitude sickness is a physiological response to hypobaric hypoxia, a condition characterized by lower atmospheric pressure and reduced oxygen availability at elevations typically exceeding 2,500 meters above sea level. The human body requires time to adapt to these changes, primarily through increased ventilation, enhanced oxygen transport via red blood cell production, and adjustments in acid-base balance. When ascent occurs too quickly, these compensatory mechanisms fail, leading to a cascade of symptoms.

The severity of altitude sickness varies depending on individual susceptibility, rate of ascent, and absolute elevation. While mild cases may resolve with rest and gradual acclimatization, severe forms such as high-altitude pulmonary edema (HAPE) or high-altitude cerebral edema (HACE) can be fatal if untreated. Risk factors include pre-existing cardiovascular or respiratory conditions, dehydration, and physical exertion at high altitudes. Prevention strategies emphasize gradual ascent, hydration, and pharmacological interventions such as acetazolamide, which accelerates acclimatization by inducing metabolic acidosis (Source: Wilderness Medical Society Practice Guidelines, 2019).

Pathophysiology

The primary trigger for altitude sickness is the reduced partial pressure of oxygen (PO₂) in inspired air, which declines exponentially with increasing elevation. At sea level, atmospheric pressure is approximately 101.3 kPa, with an oxygen concentration of 21%, yielding a PO₂ of 21.3 kPa. At 5,500 meters, however, atmospheric pressure drops to 50.6 kPa, reducing PO₂ to 10.6 kPa. This hypoxic environment impairs oxygen delivery to tissues, particularly in the brain and lungs, leading to vasodilation, increased capillary permeability, and fluid leakage into interstitial spaces.

In the brain, hypoxia induces cerebral vasodilation, raising intracranial pressure and contributing to symptoms such as headache and nausea. In the lungs, hypoxic pulmonary vasoconstriction (HPV) increases pulmonary arterial pressure, predisposing individuals to HAPE. Genetic factors, such as variations in the hypoxia-inducible factor (HIF) pathway, may influence susceptibility, though research in this area remains ongoing (Source: Journal of Applied Physiology, 2020).

Symptoms and Classification

Altitude sickness is classified into three primary syndromes: acute mountain sickness (AMS), high-altitude pulmonary edema (HAPE), and high-altitude cerebral edema (HACE). AMS is the most common and least severe form, typically manifesting within 6 to 12 hours of ascent. Symptoms include headache, fatigue, dizziness, nausea, and sleep disturbances. The Lake Louise Scoring System (LLSS), a standardized diagnostic tool, quantifies symptom severity on a scale from 0 to 15, with scores ≥3 indicating clinically significant AMS (Source: High Altitude Medicine & Biology, 2018).

HAPE and HACE represent medical emergencies requiring immediate descent and intervention. HAPE is characterized by dyspnea at rest, cough, and frothy sputum, resulting from fluid accumulation in the alveoli. HACE, the most severe form, presents with ataxia, confusion, and altered consciousness due to cerebral edema. Both conditions can progress rapidly, with mortality rates exceeding 50% if untreated (Source: The Lancet, 2017).

Application Area

• Mountaineering and Trekking: Altitude sickness is a leading cause of morbidity and mortality among climbers and trekkers in regions such as the Himalayas, Andes, and Alps. Expeditions to peaks like Mount Everest (8,848 meters) or Kilimanjaro (5,895 meters) require meticulous acclimatization schedules to mitigate risks. Commercial trekking operators often enforce rest days and gradual ascent protocols to reduce incidence rates.
• High-Altitude Tourism: Destinations such as Cusco (Peru, 3,400 meters), Lhasa (Tibet, 3,650 meters), and La Paz (Bolivia, 3,640 meters) attract millions of tourists annually. Hotels and tour agencies in these regions provide pre-acclimatization guidance, including hydration strategies and pharmacological prophylaxis. Some facilities offer portable hyperbaric chambers for emergency treatment.
• Aviation and Aerospace: Pilots and astronauts are trained to recognize symptoms of altitude sickness, particularly during rapid ascents in unpressurized aircraft or spaceflight. Pre-flight acclimatization and supplemental oxygen are standard protocols in high-altitude aviation (Source: Federal Aviation Administration, 2021).
• Military Operations: Armed forces operating in high-altitude environments, such as the Indian Army in Siachen Glacier (5,400 meters), implement strict acclimatization regimens. Soldiers undergo staged ascents and are monitored for early signs of AMS, HAPE, or HACE to ensure operational readiness.

Well Known Examples

• Mount Everest Expeditions: The 1996 Mount Everest disaster, documented in Jon Krakauer's Into Thin Air, highlighted the lethal consequences of altitude sickness. Eight climbers died after ascending too rapidly, with HAPE and HACE cited as contributing factors. This event led to revised acclimatization protocols in commercial expeditions.
• Inca Trail to Machu Picchu: The Inca Trail, a popular trekking route in Peru, reaches elevations of 4,200 meters. Tour operators enforce mandatory rest days at Wayllabamba (3,000 meters) and Dead Woman's Pass (4,215 meters) to reduce AMS incidence among hikers.
• Tibetan Plateau: The Qinghai-Tibet Railway, which ascends to 5,072 meters, incorporates pressurized cabins and oxygen supplementation to prevent altitude sickness in passengers. Despite these measures, some travelers still experience mild symptoms upon arrival in Lhasa.

Risks and Challenges

• Individual Variability: Susceptibility to altitude sickness varies widely, with some individuals experiencing severe symptoms at moderate elevations (e.g., 2,500 meters), while others remain asymptomatic at extreme altitudes. Genetic predisposition, fitness level, and prior exposure do not reliably predict risk, complicating prevention strategies.
• Misdiagnosis: Symptoms of AMS, such as headache and nausea, overlap with other conditions like dehydration, migraine, or viral infections. In remote settings, misdiagnosis can delay appropriate treatment, increasing the risk of progression to HAPE or HACE.
• Pharmacological Limitations: Acetazolamide, the most commonly prescribed prophylactic medication, is contraindicated in individuals with sulfa allergies. Dexamethasone, an alternative, carries risks of hyperglycemia and immunosuppression. No universally effective or risk-free pharmacological intervention exists.
• Logistical Constraints: In high-altitude regions, access to medical care is often limited. Helicopter evacuations, the gold standard for severe cases, may be delayed by weather conditions or terrain, increasing mortality risk. Portable hyperbaric chambers, while effective, are not universally available.
• Climate Change Impact: Melting glaciers and shifting weather patterns are altering high-altitude environments, potentially exposing travelers to new risks. For example, rapid temperature fluctuations may exacerbate dehydration, a known risk factor for altitude sickness (Source: Nature Climate Change, 2022).

Prevention and Management

Prevention of altitude sickness centers on gradual ascent, defined as limiting elevation gain to 300–500 meters per day above 2,500 meters, with a rest day every 3–4 days. Hydration, avoidance of alcohol and sedatives, and a high-carbohydrate diet are recommended to support acclimatization. Pharmacological prophylaxis with acetazolamide (125–250 mg twice daily) is advised for individuals with a history of AMS or those ascending rapidly (Source: Wilderness Medical Society, 2019).

Management of mild AMS involves halting ascent, rest, and symptomatic treatment with analgesics (e.g., ibuprofen) and antiemetics. For moderate to severe cases, immediate descent to lower elevations is critical. Supplemental oxygen (2–4 L/min) and portable hyperbaric chambers (e.g., Gamow bag) can stabilize patients during evacuation. HAPE and HACE require urgent descent, oxygen therapy, and medications such as nifedipine (for HAPE) or dexamethasone (for HACE).

Similar Terms

• Chronic Mountain Sickness (CMS): A long-term condition affecting permanent residents of high-altitude regions, characterized by excessive erythrocytosis, pulmonary hypertension, and right ventricular hypertrophy. Unlike AMS, CMS develops over years and is associated with irreversible cardiovascular changes.
• High-Altitude Retinal Hemorrhage (HARH): A condition involving bleeding in the retina due to increased intracranial pressure at high elevations. Symptoms include blurred vision and scotomas, though most cases resolve spontaneously with descent.
• Decompression Sickness (DCS): A disorder caused by rapid changes in ambient pressure, typically associated with diving or aviation. While DCS shares some symptoms with altitude sickness (e.g., joint pain, neurological deficits), its pathophysiology involves nitrogen bubble formation rather than hypoxia.

Summary

Altitude sickness is a multifaceted syndrome driven by hypobaric hypoxia, posing significant risks to travelers in high-altitude environments. Its clinical spectrum ranges from mild acute mountain sickness to life-threatening pulmonary and cerebral edema. Prevention relies on gradual ascent, hydration, and pharmacological prophylaxis, while management emphasizes early recognition and descent. Despite advances in understanding its pathophysiology, altitude sickness remains a leading cause of morbidity in mountaineering, tourism, and military operations. Future research may elucidate genetic markers for susceptibility, improving personalized prevention strategies.

--